Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO Annual Meeting

Diversity of Abstracts Reflects Continued Growth of Eisai's Commitment to

Oncology

    WOODCLIFF LAKE, N.J., May 31 /PRNewswire/ -- Eisai announced today that
 several abstracts covering clinical data about their oncology pipeline
 compounds have been accepted for presentation at the American Society of
 Clinical Oncology (ASCO) annual meeting. ASCO takes place in Chicago from
 June 1-5, 2007.
     These abstracts reveal a growing and diverse oncology clinical
 development program at Eisai. In addition to the variety of oncology
 product classes under investigation, these compounds are being studied in
 advanced diseases where there remains considerable unmet medical need,
 particularly in refractory metastatic breast cancer, advanced non-small
 cell lung cancer, and advanced ovarian cancer.
     The following abstracts highlight data from pipeline compounds that
 have been accepted for presentation at this year's ASCO meeting.
     Product        Abstract Details                        Location Details
 
     Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00
     Mesylate       (E7389) Halichondrin B Analog in        AM - 1:00 PM
     (E7389)        Patients with Refractory Breast Cancer  Location: S403
     Abstract No:   Poster Number: 21
     1034
 
 
     Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00
     Mesylate       (E7389), a Mechanistically Novel        AM - 1:00 PM
     (E7389)        Inhibitor of Microtubule Dynamics,      Location: E451a
     Abstract No:   in Patients with Advanced Non-Small
     7546           Cell Lung Cancer (nsclc)
                    Poster Number: 20
 
 
     MORAb-003      Novel Phase II Study Design of          June 2, 2007
     Abstract No:   MORAb-003, a Monoclonal Antibody        2:00 PM - 6:00 PM
     5583           against Folate Receptor Alpha in        Location: S Hall A2
                    Platinum-Sensitive Ovarian Cancer
                    in First Relapse
                    Poster Number: U4
 
 
     MORAb-003      A Phase I Study of MORAb-003, a Fully   June 2, 2007
     Abstract No:   Humanized Monoclonal Antibody against   2:00 PM - 6:00 PM
     5553           Folate Receptor Alpha, in Advanced      Location: S Hall A2
                    Epithelial Ovarian Cancer
                    Poster Number: R7
 
 
     E7974          A Phase I Trial of E7974 Administered   June 3, 2007
     Abstract No:   on Days 1 and 15 of a 28-Day Cycle in   8:00 AM - 12:00 PM
     2550           Patients With Solid Malignancies        Location: S Hall A2
                    Poster Number: B6
 
 
     E7974          A Phase I Trial of E7974 Administered   June 3, 2007
     Abstract No:   on Days 1, 8, and 15 of a 28-Day Cycle  8:00 AM - 12:00 PM
     2543           in Patients With Solid Malignancies     Location: S Hall A2
                    Poster Number: A13
     The expansion of Eisai's oncology discovery, research and clinical
 development capabilities complements the company's establishment of its
 oncology sales and marketing operations in the United States. Through its
 acquisition in 2006 of four marketed oncology products, Eisai also obtained
 key oncology personnel and expertise, including a sales force. Most
 recently, Eisai acquired Morphotek, Inc., which discovers and develops
 therapeutic monoclonal antibodies through its proprietary technologies.
 Morphotek has preclinical and clinical development programs underway in
 several therapeutic categories, including oncology. Both acquisitions
 expand Eisai's capabilities into the biologic therapeutics field.
     Eisai is committed to building its commercial oncology infrastructure
 and is well positioned to market new oncology products that originate from
 its research and discovery efforts or through future acquisition,
 co-promotion or in-licensing opportunities. That growth will help Eisai
 address the unmet medical needs of patients, especially cancer patients,
 throughout the world.
     About Eisai Inc.
     Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a
 research-based human health care (hhc) company that discovers, develops and
 markets products throughout the world. Eisai focuses its efforts in three
 therapeutic areas: neurology, gastrointestinal disorders and
 oncology/critical care. Established in 1995 and ranked among the top-20
 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began
 marketing its first product in the United States in 1997 and has rapidly
 grown to become an integrated pharmaceutical business with sales of
 approximately $2.6 billion in fiscal year 2006 (year ended March 31, 2007).
     Eisai Inc. employs approximately 1,500 people at its headquarters in
 Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and
 formulation research and development facility in Research Triangle Park,
 NC, and in the field. For more information about Eisai, please visit
 http://www.eisai.com.
     About Eisai Medical Research Inc.
     Eisai Medical Research Inc., a U.S. pharmaceutical subsidiary of Eisai
 Co., Ltd., headquartered in Ridgefield Park, NJ, is focused on clinical
 drug development of new chemical entities and of new indications for
 marketed products.
     About Morphotek, Inc.
     Morphotek(R), Inc., a U.S. subsidiary of Eisai Co., Ltd., was acquired
 by Eisai in April 2007. Founded in 2000 and located in Exton, PA, Morphotek
 is a biopharmaceutical company which discovers and develops monoclonal
 antibodies through the use of proprietary human antibody technology called
 Human MORPHODOMA(R). Morphotek has assembled a strong pipeline of lead
 products in the areas of oncology and inflammation and infectious diseases.
 It has programs in clinical development and in preclinical stage moving
 towards IND filing. For further information, visit
 http://www.morphotek.com.
     About Eisai Co., Ltd.
     Eisai Co., Ltd. is a research-based human health care company that
 discovers, develops and markets products throughout the world. Through a
 global network of research facilities, manufacturing sites and marketing
 subsidiaries, Eisai actively participates in all aspects of the worldwide
 health care system. Eisai employs more than 9,000 people worldwide.
 
 

SOURCE Eisai